Acumen Pharmaceuticals Net Income
| ABOS Stock | USD 3.31 -0.06 -1.78% |
Momentum
Buy Extended
Oversold | Overbought |
As of the 12th of March 2026, Acumen Pharmaceuticals maintains a quoted price of 3.31 per share. Short-term indicators show Mean Deviation of 3.94, risk adjusted performance of 0.1383, and Downside Deviation of 4.1. The model measures trend continuation and reversal probability using historical patterns. Comparative analytics measure deviation from sector averages.
Current projections place Total Revenue at 0.00, representing a change of NaN%. Last year, Acumen Pharmaceuticals recorded Total Revenue of 0.00. As of this month (March), Gross Profit is expected to decrease toward approximately -168.2 K. In addition to that, Pretax Profit Margin is expected to decrease toward -6.16 Examining Acumen Pharmaceuticals's income statement, balance sheet, and cash flow together gives a multi-dimensional view of its financial health and valuation potential. Key drivers are highlighted below: Gross Profit | Market Capitalization | Enterprise Value Revenue 89.674 | Revenue | Earnings Share -2.21 |
| Last Reported | Projected for Next Year | ||
| Net Loss | -92.1 M | -87.5 M | |
| Net Loss | -38.6 M | -40.5 M | |
| Net Loss | -92.1 M | -87.5 M | |
| Net Loss | -1.96 | -2.06 |
Acumen | Net Income | Build AI portfolio with Acumen Stock |
The evolution of Net Income for Acumen Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Acumen Pharmaceuticals compares to historical norms and industry peers.
Latest Acumen Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Acumen Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Acumen Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Acumen Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Acumen Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported -102.33 M | 10 Years Trend |
|
Net Income |
| Timeline |
Acumen Net Income Regression Statistics
| Arithmetic Mean | -33,184,964 | |
| Coefficient Of Variation | -114.91 | |
| Mean Deviation | 32,781,130 | |
| Median | -7,907,000 | |
| Standard Deviation | 38,133,252 | |
| Sample Variance | 1454.1T | |
| Range | 95M | |
| R-Value | -0.79 | |
| Mean Square Error | 585T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | -5,959,753 | |
| Total Sum of Squares | 23266.3T |
Acumen Net Income History
Other Fundumenentals of Acumen Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Acumen Net Income Driver Correlations
Understanding the fundamental relationships between Acumen Pharmaceuticals' financial accounts, including Net Income, is essential for accurate valuation of Acumen Pharmaceuticals. Since Acumen Pharmaceuticals' main financial indicators are all interdependent, examining their correlations is a more efficient approach.
Click cells to compare fundamentals
Understanding Acumen Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Acumen accounting equity. Acumen Pharmaceuticals' market capitalization is 203.53 M. A P/B ratio of 2.18 indicates the market values Acumen Pharmaceuticals above its accounting book value. Enterprise value stands at 107.15 M. Intrinsic value is an estimate of what Acumen Pharmaceuticals' fundamentals imply, and it may differ from market and book figures. Analytical frameworks help compare those viewpoints.
The concept of value for Acumen Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Acumen Pharmaceuticals, key inputs include a P/B ratio of 2.18, and ROE of -85.93%. Market price reflects the current exchange level formed by active bids and offers.
Acumen Pharmaceuticals 'What if' Analysis
Running a what-if backtest on Acumen Pharmaceuticals gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Acumen Pharmaceuticals' historical reward profile was stable enough to support the current thesis.
| 12/12/2025 |
| 03/12/2026 |
Starting with 0.00 in Acumen Pharmaceuticals on December 12, 2025 and exiting today would produce 0.00 in net gains. This reflects a 0.0% net return in Acumen Pharmaceuticals in total across 90 days. Acumen Pharmaceuticals has comparable peers such as Inovio Pharmaceuticals, Opus Genetics, Agenus, Alector, Seer, Seres Therapeutics, and Fate Therapeutics. This provides context for relative positioning. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treat... More
Upside and Downside Indicators for Acumen Pharmaceuticals Snapshot
These indicators describe how Acumen Pharmaceuticals momentum evolves across recent price ranges. They provide a structured view of short-term momentum and range behavior.
| Downside Deviation | 4.1 | |||
| Information Ratio | 0.1695 | |||
| Maximum Drawdown | 38.93 | |||
| Value At Risk | -6.53 | |||
| Potential Upside | 9.18 |
Market Risk Indicators for Acumen Pharmaceuticals Snapshot
Risk measures here provide context on Acumen Pharmaceuticals' return distribution and drawdown behavior. The signals are informational and describe volatility patterns.| Risk Adjusted Performance | 0.1383 | |||
| Jensen Alpha | 0.942 | |||
| Total Risk Alpha | 1.1 | |||
| Sortino Ratio | 0.2364 | |||
| Treynor Ratio | -3.25 |
Investors who believe in mean reversion view Acumen Pharmaceuticals' price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
Acumen Pharmaceuticals Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1383 | |||
| Market Risk Adjusted Performance | -3.24 | |||
| Mean Deviation | 3.94 | |||
| Semi Deviation | 3.38 | |||
| Downside Deviation | 4.1 | |||
| Coefficient Of Variation | 596.75 | |||
| Standard Deviation | 5.72 | |||
| Variance | 32.69 | |||
| Information Ratio | 0.1695 | |||
| Jensen Alpha | 0.942 | |||
| Total Risk Alpha | 1.1 | |||
| Sortino Ratio | 0.2364 | |||
| Treynor Ratio | -3.25 | |||
| Maximum Drawdown | 38.93 | |||
| Value At Risk | -6.53 | |||
| Potential Upside | 9.18 | |||
| Downside Variance | 16.8 | |||
| Semi Variance | 11.45 | |||
| Expected Short fall | -4.69 | |||
| Skewness | 2.2 | |||
| Kurtosis | 10.24 |
Acumen Pharmaceuticals Backtested Returns
Acumen Pharmaceuticals shows an elevated risk exposure relative to the chosen timeframe. It records an Efficiency (Sharpe) Ratio of 0.15, marking performance variability over 3 months. We identified twenty-nine technical indicators influencing the company's volatility profile. Please evaluate metrics such as Downside Deviation of 4.1, risk-adjusted performance of 0.1383, and mean deviation of 3.94 to review standard deviation behavior. On a scale of 0 to 100, Acumen Pharmaceuticals holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of -0.29, which alludes to relatively modest fluctuations relative to the market. As returns on the market increase, returns on Acumen Pharmaceuticals tend to move in the opposite direction, though by a smaller magnitude. During a bear market, however, Acumen Pharmaceuticals is likely to outperform the market. Please validate Acumen Pharmaceuticals' the relationship between the skewness and day median price, to make a quick decision on whether Acumen Pharmaceuticals' current price history will revert.
Auto-correlation | -0.37 |
Poor reverse predictability
Acumen Pharmaceuticals exhibits poor reverse predictability. Autocorrelation measures the degree of predictability between Acumen Pharmaceuticals time series from 12th of December 2025 to 26th of January 2026 and from 26th of January 2026 to 12th of March 2026. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of Acumen Pharmaceuticals may be projected. A serial correlation of -0.37 indicates that just about 37.0% of current Acumen Pharmaceuticals price fluctuations can be explained by its historical price movements. Given that Acumen Pharmaceuticals has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.37 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Acumen Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income | -57,960 |
Based on the recorded statements, Acumen Pharmaceuticals reported net income of -102.33 Million. This is 129.98% lower than that of the Biotechnology sector and 246.09% lower than that of the Health Care industry. The net income for all United States stocks is 117.92% higher than that of the company.
Acumen Net Income Peer Comparison
Stock peer comparison using Net Income is a widely accepted method for assessing the relative value of Acumen Pharmaceuticals within its competitive group. By comparing Acumen Pharmaceuticals' Net Income to that of similar stocks, investors can identify undervalued securities or stronger alternatives for their.Acumen Pharmaceuticals is currently under evaluation. in net income category among its top competitors.
Acumen Pharmaceuticals Current Valuation Drivers
Key valuation indicators for Acumen Pharmaceuticals are extracted from Acumen Pharmaceuticals' financial statements and used to compute various performance and valuation scores. These drivers assess Acumen Pharmaceuticals' profitability relative to revenue, cost structure, and shareholder equity.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Enterprise Value | 532.1M | 136.5M | 89.3M | 97.3M | 111.9M | 106.3M |
Acumen Pharmaceuticals ESG Sustainability
Firms with strong ESG performance, including Acumen Pharmaceuticals, may command higher valuations from investors. While Acumen Pharmaceuticals' sustainability disclosures are mostly voluntary, they communicate a commitment to responsible governance and long-term risk management.Environmental | Governance | Social |
Acumen Pharmaceuticals Institutional Holders
The institutional ownership base of Acumen Pharmaceuticals consists of large financial organizations, pension funds, and endowments that hold stakes in Acumen Pharmaceuticals' shares. Institutional investors often accumulate meaningful positions and use their influence to engage with Acumen Pharmaceuticals'.| Shares | Millennium Management Llc | 2025-09-30 | 601.7 K | Citadel Advisors Llc | 2025-09-30 | 494.1 K | Renaissance Technologies Corp | 2025-12-31 | 423.1 K | Two Sigma Advisers, Llc | 2025-12-31 | 421.8 K | Sg Americas Securities, Llc | 2025-09-30 | 403.9 K | Geode Capital Management, Llc | 2025-09-30 | 398.8 K | Ikarian Capital, Llc | 2025-09-30 | 265.8 K | Susquehanna International Group, Llp | 2025-09-30 | 214.4 K | Bank Of America Corp | 2025-09-30 | 213.7 K | Ra Capital Management, Llc | 2025-12-31 | 14.9 M | Sands Capital Ventures, Llc | 2025-12-31 | 3.4 M |
Acumen Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 107.15 M | ||||
| Shares Outstanding | 60.57 M | ||||
| Shares Owned By Insiders | 7.46 % | ||||
| Shares Owned By Institutions | 64.65 % | ||||
| Number Of Shares Shorted | 960.88 K | ||||
| Price To Book | 2.18 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | -118.93 M | ||||
| EBITDA | -98.08 M | ||||
| Net Income | -102.33 M | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 29.7 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | -86.22 M | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | -2.21 X | ||||
| Price To Earnings To Growth | -0.23 X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.21 | ||||
| Market Capitalization | 203.53 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | -325.13 M | ||||
| Working Capital | 150.7 M | ||||
| Net Asset | 238.99 M |
About Acumen Pharmaceuticals Fundamentals
Acumen Pharmaceuticals reports ROE of -85.93%. Understanding Acumen Pharmaceuticals begins with reviewing capital efficiency and profitability trajectory. Earnings persistence strengthens confidence in forecast stability. Acumen Pharmaceuticals reports EPS of -2.21, current ratio of 37.21. 
Michael Smolkin ยท Member of Macroaxis Board of Directors
Unless otherwise specified, financial data for Acumen Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Acumen Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Acumen Stock is Curated By:
Michael Smolkin ยท Member of Macroaxis Board of DirectorsThematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |